최근 개발된 B-세포 림프종의 치료 약제

초록

While most B-cell lymphomas are cured by chemotherapy, in recent years research interest has focused on the development of monoclonal antibodies and small molecules targeting membrane proteins, components of signaling pathways or tumor micro-environment, which are factors essential for the development and progression of lymphomas. Some of these new drugs have shown substantial clinical activity in phase I and small phase II studies in patients with relapsed and refractory disease, with response rates of up to 50-60% in some cases. These results give hope for patients who have standard treatment failure; however, their incorporation into commonly used regimens also represents a significant challenge for the future.

키워드